Updated:
Virbac SA/ADR
Virbac SA is a French animal-health company founded in 1968, focused on veterinary pharmaceuticals and vaccines for companion animals and livestock.
Virbac SA/ADR
Virbac was founded in 1968 by veterinarian Pierre-Richard Dick in Carros, near Nice, France. The company originally focused on developing veterinary pharmaceuticals for companion animals and livestock, a niche it has maintained as its core. Today Virbac is publicly traded on Euronext Paris (EPA: VIRP) and remains under the founding family's influence through a controlling stake held by the Dick family (per public filings). The firm's strategy centers on prescription and over-the-counter animal-health products, including vaccines, parasiticides, anti-infectives, and dermatological treatments. It also operates a diagnostics division. Virbac's geographic footprint spans Europe, North America, Latin America, Asia-Pacific, Africa, and the Middle East. Key markets include the United States, France, Australia, and Brazil. In 2024, Virbac acquired the U.S. animal-health business of Bimeda, expanding its presence in the North American market (per Virbac press release, 2024). As of 2024, Virbac employed approximately 5,500 people worldwide. The company has R&D centers in France, the U.S., and Australia. Adjacent to its pharmaceutical business, Virbac operates a veterinary diagnostics arm. A recent operational event: In March 2025, Virbac announced the appointment of Sébastien Huron as CFO, succeeding Jérôme Ponte (per Virbac announcement, March 2025). A structural differentiator: Virbac is one of the few independent, pure-play animal-health companies of significant scale that is not a division of a larger human-pharma conglomerate. Its founding-family control provides a long-term strategic horizon distinct from the quarterly focus typical of widely held pharma companies.
General information
Firm type
Publicly Traded Company
Year founded
1968
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Carros
Corporate office
Carros, France
Principals
Pierre Dick
Chief Executive Officer
Sébastien Huron
Chief Financial Officer
Sector focus
Frequently asked questions
Who controls Virbac after going public?
The founding Dick family retains a controlling stake in Virbac through a holding company. While the firm is publicly traded on Euronext Paris, the family's voting power and board representation ensure continued strategic influence (per public filings).
What is Virbac's core business vs. larger animal-health competitors?
Virbac is a pure-play animal-health company, unlike Zoetis, Elanco, or Merck Animal Health which are divisions of diversified pharmaceutical conglomerates. Virbac focuses specifically on veterinary drugs, vaccines, and diagnostics, with a particular emphasis on companion animals (dogs and cats) and livestock. This specialization allows it to compete effectively in niche therapeutic areas.
Does Virbac have a significant presence in the U.S. market?
Yes, the United States is one of Virbac's largest markets. The company has a subsidiary, Virbac Corporation, based in Fort Worth, Texas. In 2024, Virbac expanded its U.S. footprint by acquiring Bimeda's U.S. animal-health business (per Virbac press release, 2024).
What are Virbac's major product categories?
Virbac's product portfolio includes vaccines (for dogs, cats, horses, and livestock), parasiticides (such as flea and tick treatments), anti-infectives, dermatological products, and nutritional supplements. The company also produces diagnostic kits and imaging products for veterinary use.
How does Virbac approach research and development?
Virbac invests approximately 5% of its annual revenue into R&D. Its R&D facilities are located in France, the United States, and Australia. The company focuses on developing novel vaccines and therapeutic solutions for under-served animal diseases, often in collaboration with academic institutions and other research organizations.
Is Virbac involved in any philanthropic or sustainability initiatives?
Virbac operates a corporate foundation, the Virbac Foundation, which supports research and education in veterinary medicine. The company also publishes sustainability reports aligned with global standards, focusing on reducing its environmental footprint and advancing animal welfare (per Virbac's website).
What is the geographic breakdown of Virbac's revenue?
Virbac generates revenue across all major regions. In its 2023 annual report, the firm reported approximately 34% of sales in Europe, 25% in the Americas, 20% in Asia-Pacific, and 21% in Africa and the Middle East. The U.S. and France are its largest individual country markets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: